Cardiovascular disease biotech company Corsera Health has secured $80 million in a Series A funding round, as the company’s lead siRNA candidate enters clinical trials. The fundraising was co-led by Forbion and Population Health Partners, with participation from co-CEO and founder John Maraganore.
Corsera Health was recently recognized as one of BioSpace’s NextGen companies to watch. Founded in September 2025, the company is focused on extending healthspan by reducing the risk of atherosclerotic cardiovascular disease (ASCVD). Its approach combines an AI-enabled tool for predicting lifetime ASCVD risk with therapies designed for annual administration to prevent disease onset.
The company's two main programs use siRNA technology to silence genes involved in cardiovascular risk: PCSK9, which influences LDL-cholesterol levels, and angiotensinogen (AGT), which affects blood pressure. The lead program, COR-1004, is an siRNA therapy targeting PCSK9. Corsera announced that COR-1004 has now entered a Phase I clinical trial, where dosing has begun. This initial study will assess safety and tolerability of the injectable drug and will also measure its impact on plasma PCSK9 and serum LDL-C levels. Initial proof-of-concept data are expected later this year.
A second program, COR-2003, targets AGT to reduce blood pressure and is expected to enter Phase I testing soon.
Corsera Health was founded by John Maraganore—former CEO of Alnylam—and Clive Meanwell, who previously cofounded Metsera and served as its CEO.
"From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye," according to BioSpace’s NextGen report.
